LENZ Therapeutics (LENZ) Retained Earnings (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Retained Earnings of -$268.6 million for Q1 2026, down 68.31% year-over-year from -$847.8 million in Q1 2025, and down 18.27% quarter-over-quarter from -$227.1 million in Q4 2025.
LENZ Therapeutics (LENZ) Retained Earnings (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Retained Earnings for 7 consecutive years, with -$268.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 68.31% year-over-year to -$268.6 million; the TTM figure through Mar 2026 stood at -$268.6 million (down 68.31% YoY), while the FY2025 annual figure was -$227.1 million, down 56.63% from the prior year.
- Retained Earnings slipped to -$268.6 million in Q1 2026 per LENZ's latest filing, from -$227.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $548.2 million in Q3 2023 and bottomed at -$321.7 million in Q2 2023.
- Historically, Retained Earnings has averaged -$37.3 million across 5 years, with a median of -$122.1 million in 2024.
- On a YoY basis, Retained Earnings climbed as much as 34451.44% in 2023 and fell as far as 86093.2% in 2023.
- LENZ Therapeutics' Retained Earnings stood at $539.7 million in 2022, then tumbled by 117.65% to -$95.2 million in 2023, then plunged by 52.25% to -$145.0 million in 2024, then plunged by 56.63% to -$227.1 million in 2025, then fell by 18.27% to -$268.6 million in 2026.
- Business Quant data shows LENZ's Retained Earnings at -$268.6 million in Q1 2026, -$227.1 million in Q4 2025, and -$191.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 520.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 520.44 Mn |
| Mar 31, 2026 | -268.63 Mn |
| Dec 31, 2025 | -227.14 Mn |
| Sep 30, 2025 | -191.20 Mn |
| Jun 30, 2025 | 380.87 Mn |
| Mar 31, 2025 | -159.60 Mn |
| Dec 31, 2024 | -145.01 Mn |
| Sep 30, 2024 | 523,000.00 |
| Jun 30, 2024 | -122.15 Mn |
| Mar 31, 2024 | -111.90 Mn |
| Dec 31, 2023 | -95.25 Mn |
| Sep 30, 2023 | 548.25 Mn |
| Jun 30, 2023 | -321.70 Mn |
| Mar 31, 2023 | -266.34 Mn |
| Dec 31, 2022 | 539.74 Mn |
| Sep 30, 2022 | -1.60 Mn |
| Jun 30, 2022 | -193.10 Mn |
| Mar 31, 2022 | -309,000.00 |
| Dec 31, 2021 | 525.40 Mn |
| Sep 30, 2021 | -122.42 Mn |